HZNP - Horizon Therapeutics Public Limited Company
| Previous Close | 24.60 |
| Open | 24.66 |
| Bid | 24.49 x 4000 |
| Ask | 25.44 x 1300 |
| Day's Range | 24.66 - 25.34 |
| 52 Week Range | 15.75 - 29.44 |
| Volume | 1,368,195 |
| Avg. Volume | 1,981,333 |
| Market Cap | 4.591B |
| Beta (3Y Monthly) | 1.19 |
| PE Ratio (TTM) | 103.03 |
| EPS (TTM) | 0.24 |
| Earnings Date | May 27, 2019 - May 31, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.50 |
- Business Wire•6 days ago
Horizon Named One of the Best Workplaces in Chicago by Great Place to Work® and FORTUNE
Horizon Therapeutics plc (HZNP) today announced that it has been selected to the FORTUNE and Great Place to Work® 2019 “Best Workplaces in Chicago” list. “We are proud to be recognized as one of the Best Workplaces in Chicago for the third consecutive year,” said Irina Konstantinovsky, executive vice president, chief human resources officer, Horizon.
- Business Wire•11 days ago
Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout
Horizon Therapeutics plc (HZNP) today announced the launch of Gout Lies, a data-driven campaign to reframe physician dialogue on the reality of living with gout and underscore findings of recent research that warrant a new view on how to properly manage the disease. Through a mix of thought-provoking visuals, expert videos and clinical data, the campaign is designed to inform a modern dialogue about the impact of gout. The goal is to specifically advance the understanding of the complex relationship between pain resolution and gout progression, given the unique mechanism that resolves acute pain in gout often results in patients delaying discussions with the physician.
- Thomson Reuters StreetEvents•13 days ago
Edited Transcript of HZNP earnings conference call or presentation 8-May-19 12:00pm GMT
Q1 2019 Horizon Pharma PLC Earnings Call
- TipRanks•15 days ago
Market Weekly Review: China Trade Dispute Hits Stocks
Needless to say, this week got off to an ominous start for bulls, before Monday morning even rolled around. Despite a late rally on Friday that snapped a four-day losing streak in the U.S. markets, it still ended as the worst week in 2019 for the S&P 500. The CBOE Volatility Index (VIX) jumped 25% on Tuesday on top of a 20% gain on Monday, before declining 16% on Friday. When the dust settled, global markets had lost $1.451 trillion of value this week, according to Howard Silverblatt of S&P Dow Jones Indices.Selling pressure started over the weekend, when most investors probably weren’t even thinking about stocks. President Trump fired off a tweet last Sunday, suggesting the U.S. would raise tariffs on $200 billion of Chinese goods from 10% to 25% on Friday and consider taxing another $325 billion of items.A war of words ensued on both sides and the news kicked off a roller coaster ride in the global markets. The U.S. followed through with its threats on Friday and the Chinese have promised retaliatory trade actions. Looking AheadEarnings season officially ended this week, but several blue-chip names are still on the calendar to report quarterly results next week, highlighted by Cisco Systems (CSCO) on Wednesday and Wal-Mart (WMT) on Thursday.75% of companies in the S&P 500 exceeded profit estimates this quarter, which is above the historical average of 67%. The best growth was from the healthcare sector, while energy names were a drag on overall growth. Four weeks ago, aggregate earnings were expected to fall 3% to 4% year-over-year, but the actual results yielded a 1.2% increase.It appears that we managed to escape an earnings recession in the first quarter, but volatility has reared its ugly head again this week.After a hot start to the year, when the major U.S. stock market averages gained at least 14% through April, it’s scary to see how quickly those gains can evaporate. More than once this week, investors woke up to the news that the Dow Jones Industrial Average was set to open down 500 points or more.However, the fact remains that attractive investments are out there, if you’re willing to dig a little deeper. That’s where we come in.Because one such healthcare name that’s worth a closer look is our Stock of the Week below… Stock of the Week: Horizon Pharma (HZNP \- Research Report)Horizon was a breath of fresh air in a volatile week for investors. Management posted quarterly results on Wednesday that handily exceeded analyst expectations. Excluding one-time items, the company earned $0.30 a share in the first quarter. Revenue increased 25% from the previous year to $280 million and also came in ahead of expectations. We recently added HZNP to our Smart Investor portfolio and are pleased to see that shares soared 5.7% in the last week alone. Looking ahead, these gains should keep on coming. Here’s why: Treating Rare Diseases with Orphan DrugsThe company offers investors a little bit of everything, from growth at a reasonable price, to a pipeline bursting with opportunities in rheumatology and rare diseases.Horizon currently has 11 products on the market, led by Krystexxa, for uncontrollable gout. The company’s expertise is in rare diseases, where the majority of its revenue is generated. Management believes that Krystexxa can ultimately generate up to $750 million of annual sales in the U.S. and Horizon is currently seeking approval for two new indications, to increase the product’s addressable market. In late April, Horizon also said that Phase 3 studies for teprotumumab, its thyroid eye disease (TED) treatment, met primary and secondary endpoints. Management plans to file a Biologics License Application with the U.S. Food and Drug Administration (FDA) later this year. TED affects 15k-20k patients each year in the U.S. and there are no existing FDA-approved treatments. Teprotumumab has already been designated an orphan drug, with fast-track and breakthrough therapy status. The company estimates the product could also generate $750 million of peak annual revenue in the U.S. Analysts See Continued UpsideEarlier this month, Liav Abraham of Citigroup upgraded the stock from Neutral to Buy. Seven of nine active analysts now rate Horizon a Buy and the average price target of $32.22 suggests 14.8% upside from current levels.“Post a 1Q19 beat, we are reiterating our OW rating and 12- month PT of $32. We continue to expect upside to FactSet estimates for HZNP's orphan as well as rheumatology businesses and multiple expansion to drive the stock higher” wrote top-ranked Cantor Fitzgerald analyst Louise Chen recently. View HZNP Price Target & Analyst Ratings DetailThe analyst community calls for the company to deliver 18.1% compound earnings growth over the next two years. In the meantime, Horizon trades at just 16x expected 2019 earnings of $1.75 a share, which suggests that its price has room to grow. Management is using these profits to improve the balance sheet. Coupled with proceeds from an equity offering in March, the company plans to pay down $550 million of debt this year.Finally, I’m encouraged to note the stock sports a Smart Score of 10/10 on TipRanks, suggesting the potential for continued price momentum. This new proprietary metric utilizes Big Data to rank stocks based on 8 key factors that have historically been a precursor to future outperformance.View HZNP Smart Score DetailIn addition to the catalysts mentioned above, Smart Score notes that Horizon has positive technical momentum and sentiment from bloggers and investors.FYI: This is just 1 of the 20+ stocks selected for the Smart Investor portfolio. That’s where we share more detailed insights on our weekly stock picks. You may also want to learn more about how we use TipRanks indicators to find stocks that are primed to outperform. Discover the Smart Investor portfolio here >> Wishing you a world of investment success!
- Zacks•17 days ago
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
- Business Wire•18 days ago
Horizon Therapeutics plc Announces Tina Ventura as a Healthcare Businesswomen's Association 2019 Luminary
Horizon Therapeutics plc (HZNP) announced today that Tina Ventura, senior vice president, investor relations, has been named a 2019 Healthcare Businesswomen's Association (HBA) Luminary. Tina will be honored today at the 30th annual Woman of the Year event in New York. The HBA is the leading not-for-profit global organization committed to furthering the advancement and impact of women in healthcare worldwide.
- Investor's Business Daily•18 days ago
Top-Rated Pharma Stock Nears Breakout After Earnings Trounce Views
Horizon Therapeutics stock edged closer to a breakout Wednesday after the pharmaceutical company topped first-quarter expectations, though a key gout treatment lagged Street forecasts.
- Motley Fool•18 days ago
Here's How Horizon Therapeutics Blew Past Wall Street Estimates in Q1
Strong growth for its orphan, rheumatology, and primary care drugs translated to a great first quarter for Horizon.
Motley Fool•19 days agoHorizon Pharma PLC (HZNP) Q1 2019 Earnings Call Transcript
HZNP earnings call for the period ending March 31, 2019.
- Zacks•19 days ago
Horizon Pharma (HZNP) Q1 Earnings and Revenues Top Estimates
Horizon Pharma (HZNP) delivered earnings and revenue surprises of 200.00% and 18.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•19 days ago
Horizon Pharma: 1Q Earnings Snapshot
On a per-share basis, the Dublin-based company said it had a loss of 19 cents. Earnings, adjusted for non-recurring costs, came to 30 cents per share. The results surpassed Wall Street expectations. The ...
- Business Wire•19 days ago
Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
-- First-Quarter 2019 Net Sales of $280.4 Million Increased 25 Percent; First-Quarter 2019 GAAP Net Loss of $32.9 Million; Adjusted EBITDA of $88.4 Million --
- Reuters•19 days ago
RPT In Canada, a little-known drug regulator shows its teeth
A tiny, little-known government agency is ramping up regulation of Canada's pharmaceutical industry, seeking to rein in prices for patented drugs that are among the highest in the world, according to industry sources and a Reuters analysis of government data. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs, including a rare-disease medication made by Horizon Pharma that can cost C$325,000 ($253,409) a year, documents reviewed by Reuters shows. The agency can challenge the list price of any patented drug in Canada and order companies to repay some revenue.
- Reuters•19 days ago
In Canada, a little-known drug regulator shows its teeth
A tiny, little-known government agency is ramping up regulation of Canada's pharmaceutical industry, seeking to rein in prices for patented drugs that are among the highest in the world, according to industry sources and a Reuters analysis of government data. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs, including a rare-disease medication made by Horizon Pharma that can cost C$325,000 ($253,409) a year, documents reviewed by Reuters shows. The agency can challenge the list price of any patented drug in Canada and order companies to repay some revenue.
- Zacks•19 days ago
What's in Store for Axsome (AXSM) This Earnings Season?
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
- Zacks•19 days ago
What's in the Cards for AcelRx (ACRX) This Earnings Season?
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
- Zacks•20 days ago
Guardant Health (GH) to Report Q1 Earnings: What's in Store?
At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.
- Zacks•20 days ago
Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.
- Markit•20 days ago
See what the IHS Markit Score report has to say about Horizon Pharma PLC.
Horizon Pharma PLC NASDAQ/NGS:HZNPView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for HZNP with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting HZNP. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.30 billion over the last one-month into ETFs that hold HZNP are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•20 days ago
What's in Cards for Cumberland (CPIX) This Earnings Season?
Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.
- Zacks•20 days ago
Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.
- Investor's Business Daily•21 days ago
Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
The best pharmaceutical stocks to buy have commonalities: Strong Composite Ratings and Relative Strength Ratings.
- Zacks•21 days ago
Cronos (CRON) to Report Q1 Earnings: What's in the Cards?
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.
- Business Wire•21 days ago
Horizon Therapeutics plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Horizon Therapeutics plc (HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees. The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4). Horizon Therapeutics plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases.
- Zacks•23 days ago
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?
Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.
